ECO 2026 12 - 15 May 2026

Once-Weekly Subcutaneous CagriSema Does Not Affect the Exposure of Atorvastatin or Warfarin in People Living With Overweight or Obesity

Authors :

Valdemar Funch Uhre¹; Niels-Peter Becker¹; Katrine Kirkeby¹; Michal Tomasz Marzec¹; Gaetano Morelli²; Louise Witten¹

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Download .PDF

Keywords

Obesity

Congress poster

GLP-1 RA

Cagrilintide

Pre-clinical